NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,183,619 | +3.6% | 12,061,147 | +0.0% | 0.00% | – |
| Q2 2023 | $6,934,719 | -49.9% | 12,056,187 | -38.8% | 0.00% | – |
| Q1 2023 | $13,853,060 | -73.4% | 19,708,437 | -14.6% | 0.00% | -100.0% |
| Q4 2022 | $52,128,652 | -29.7% | 23,065,775 | -0.4% | 0.00% | -50.0% |
| Q3 2022 | $74,128,000 | -5.3% | 23,164,944 | +12.4% | 0.00% | 0.0% |
| Q2 2022 | $78,300,000 | -25.2% | 20,605,212 | +6.0% | 0.00% | 0.0% |
| Q1 2022 | $104,729,000 | -58.1% | 19,430,385 | +5.0% | 0.00% | -66.7% |
| Q4 2021 | $250,095,000 | -18.6% | 18,511,911 | +8.2% | 0.01% | -25.0% |
| Q3 2021 | $307,264,000 | +5.3% | 17,108,265 | +0.6% | 0.01% | +14.3% |
| Q2 2021 | $291,815,000 | -12.7% | 17,005,546 | +1.7% | 0.01% | -22.2% |
| Q1 2021 | $334,276,000 | +20.8% | 16,713,831 | +2.7% | 0.01% | +12.5% |
| Q4 2020 | $276,634,000 | +5.3% | 16,272,585 | +2.8% | 0.01% | -11.1% |
| Q3 2020 | $262,682,000 | -31.3% | 15,833,777 | -4.0% | 0.01% | -35.7% |
| Q2 2020 | $382,160,000 | +29.6% | 16,500,862 | -0.1% | 0.01% | +7.7% |
| Q1 2020 | $294,903,000 | -15.4% | 16,521,184 | +2.3% | 0.01% | +8.3% |
| Q4 2019 | $348,762,000 | +7.4% | 16,157,611 | -9.4% | 0.01% | 0.0% |
| Q3 2019 | $324,743,000 | -50.7% | 17,828,305 | -3.7% | 0.01% | -52.0% |
| Q2 2019 | $658,684,000 | +8.0% | 18,512,772 | +2.0% | 0.02% | +4.2% |
| Q1 2019 | $610,062,000 | +1.4% | 18,156,579 | -0.8% | 0.02% | -11.1% |
| Q4 2018 | $601,670,000 | -47.8% | 18,304,531 | -3.3% | 0.03% | -40.0% |
| Q3 2018 | $1,153,525,000 | +29.4% | 18,922,650 | +3.6% | 0.04% | +21.6% |
| Q2 2018 | $891,721,000 | -51.3% | 18,261,743 | +6.0% | 0.04% | -53.8% |
| Q1 2018 | $1,830,788,000 | +107.0% | 17,229,321 | +16.3% | 0.08% | +105.1% |
| Q4 2017 | $884,590,000 | +157.7% | 14,812,307 | +3.6% | 0.04% | +143.8% |
| Q3 2017 | $343,284,000 | +25.3% | 14,303,480 | +2.1% | 0.02% | +23.1% |
| Q2 2017 | $273,893,000 | -14.2% | 14,009,894 | +3.0% | 0.01% | -18.8% |
| Q1 2017 | $319,379,000 | +100.6% | 13,607,980 | +4.9% | 0.02% | +77.8% |
| Q4 2016 | $159,182,000 | -20.1% | 12,973,280 | +11.9% | 0.01% | -25.0% |
| Q3 2016 | $199,110,000 | +20.1% | 11,589,574 | -0.5% | 0.01% | +20.0% |
| Q2 2016 | $165,787,000 | +6.2% | 11,650,468 | +2.7% | 0.01% | 0.0% |
| Q1 2016 | $156,052,000 | -11.5% | 11,349,223 | +8.4% | 0.01% | -16.7% |
| Q4 2015 | $176,351,000 | +57.7% | 10,465,889 | +2.5% | 0.01% | +200.0% |
| Q3 2015 | $111,862,000 | -10.1% | 10,206,377 | +2.7% | 0.00% | -50.0% |
| Q2 2015 | $124,378,000 | +29.3% | 9,942,273 | +13.7% | 0.01% | +14.3% |
| Q1 2015 | $96,165,000 | -25.3% | 8,742,249 | +5.3% | 0.01% | -22.2% |
| Q4 2014 | $128,719,000 | +31.3% | 8,304,449 | +2.3% | 0.01% | +12.5% |
| Q3 2014 | $98,008,000 | -5.4% | 8,119,924 | +0.5% | 0.01% | 0.0% |
| Q2 2014 | $103,589,000 | +4.9% | 8,080,240 | -0.8% | 0.01% | 0.0% |
| Q1 2014 | $98,742,000 | +15.6% | 8,147,071 | +8.2% | 0.01% | 0.0% |
| Q4 2013 | $85,436,000 | +16.1% | 7,527,438 | +6.9% | 0.01% | +14.3% |
| Q3 2013 | $73,604,000 | -6.6% | 7,043,369 | +3.2% | 0.01% | -12.5% |
| Q2 2013 | $78,817,000 | – | 6,824,033 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |